

There From the Beginning on DIR Advocacy



	NCPA & Member Comments	Congressional Letters	Stakeholder Letters	Patient/Consumer Org. Letters
'14	NCPA submits comments to CMS Mar.			
'15	NCPA submits comments to CMS Jan.	Guidance on DIR Jan. 11 REPRESENTATIVES		
'16	NCPA secures introduction of DIR federal legislation Sept.	Guidance on DIR Sept. 16 SENATORS 30 REPRESENTATIVES	Support first DIR bill Sept. 99 SIGNATORIES	Asked CMS to finalize DIR guidance June 8 SIGNATORIES
'17	NCPA submits comments to CMS on DIR reporting June		Support DIR legislation Mar. 118 SIGNATORIES	
'18	DIR Proposal Jan. 992 MEMBER COMMENTS	Support DIR Proposal Jan. 21 SENATORS 80 REPRESENTATIVES	Joint comment to DIR Proposal Jan. 120 SIGNATORIES	Support elimination of pharmacy DIR Jan. 9 SIGNATORIES
	Drug Pricing RFI July 1,955 MEMBER COMMENTS	Address DIR in RFI Aug. 21 SENATORS 83 REPRESENTATIVES	Response to POTUS on Drug Pricing Blueprint July 153 SIGNATORIES	
'19	DIR Proposed Rule Jan. 3,493 MEMBER COMMENTS	Support DIR Proposal Mar. 29 SENATORS 62 REPRESENTATIVES	Response to DIR Proposed Rule Jan. 155 SIGNATORIES	Urged CMS to finalize DIR proposal Jan. 24 SIGNATORIES

NCPA Advocacy Center Meetings with Administration
April 2018: White House, OMB; May 2018: CMS; July 2018: HHS; August 2018: HHS; September 2018: White House, Domestic Policy Council; October 2018: HHS, Small Business Administration; November 2018: HHS, CMS, White House, OMB; December 2018: HHS, White House, Political Office; January 2019: White House, Domestic Policy Council; February 2019: HHS; April 2019: HHS, Small Business Administration.

National Survey Supports Pharmacy-Related Part D Reforms
June 2018: NCPA commissioned Morning Consult national survey showed overwhelming support for prohibiting PBMs from charging DIR fees to pharmacies - fees that also artificially raise seniors' out-of-pocket costs.

This summary is not an all inclusive analysis of our efforts just a highlight of major NCPA activity.